Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C

World Journal of Gastroenterology

Volumn 14, Issue 38, 2008, Pages 5913-5915

  Azim, James ^a   McCurdy, Heather ^a   Moseley, Richard H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Hemochromatosis; Hepatitis C virus; Pegylated interferon; Porphyria; Ribavirin

Indexed keywords

FERRITIN; HEPTACARBOXYPORPHYRIN; HFE PROTEIN; PEGINTERFERON ALPHA2B; PORPHYRIN; RIBAVIRIN; TRANSFERRIN; UNCLASSIFIED DRUG; UROPORPHYRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; PEGINTERFERON ALFA-2B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; GENE MUTATION; HEMOLYTIC ANEMIA; HEPATITIS C; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; LIVER FIBROSIS; MALE; PORPHYRIA CUTANEA TARDA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; GENETICS; HEMOCHROMATOSIS; MIDDLE AGED; MUTATION; PHLEBOTOMY;

ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON ALFA-2B; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; RIBAVIRIN;

EID: 63449114357     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5913     Document Type: Article

References (20)

1. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998; 18: 67-75
2. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39: 620-627
3. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44: 525-528
4. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43: 529-533
5. Siegel LB, Eber BB. Porphyria cutanea tarda remission. Ann Intern Med 1994; 121: 308-309
6. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22: 249-250
7. Jessner W, Der-Petrossian M, Christiansen L, Maier H, Steindl-Munda P, Gangl A, Ferenci P. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 2002; 36: 1301-1302
8. Thevenot T, Bachmeyer C, Hammi R, Dumouchel P, Ducamp-Posak I, Cadranel JF. Occurrence of porphyria cutanea tarda during peginterferon/ ribavirin therapy for chronic viral hepatitis C. J Hepatol 2005; 42: 607-608
9. Frider B, Buonsante ME, Tiscornia J, Alessio A, Pellerano G. [Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin] Acta Gastroenterol Latinoam 2006; 36: 38-41
10. Lambrecht RW, Thapar M, Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis 2007; 27: 99-108
11. Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol 2007; 5: 142-151
12. Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis 2004; 8: 807-838, viii
13. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RW. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-1669
14. Furuta M, Kaito M, Gabazza E, Fujita N, Ishida S, Tamaki S, Ikeda R, Wakisawa S, Hayashi H, Watanabe S, Adachi Y. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 2000; 35: 60-62
15. Bauza A, Espana A, Lloret P. Porphyria cutanea tarda, dermatomyositis and non-Hodgkin lymphoma in virus C infection. Eur J Dermatol 2003; 13: 302-304
16. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005; 25: 461-472
17. Fargion S, Fracanzani AL. Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J Hepatol 2003; 39: 635-638
18. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004
19. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21: 1109-1112
20. Fiel MI, Schiano TD, Guido M, Thung SN, Lindsay KL, Davis GL, Lewis JH, Seeff LB, Bodenheimer HC Jr. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am J Clin Pathol 2000; 113: 35-39